AvengeBio

Cambridge, United States

AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors.

$45.0M raised

Jan 2022

Series A

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has AvengeBio raised?

AvengeBio has raised $45.0M in total funding. The most recent round was Series A. The last funding was announced in January 2022.

Who are AvengeBio's investors?

AvengeBio's investors include Perceptive Advisors, Longitude Capital, Rock Springs Capital, Pappas Capital, CAM Capital.

Where is AvengeBio headquartered?

AvengeBio is headquartered in Cambridge, United States.

What does AvengeBio do?

AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors.

What stage is AvengeBio at?

AvengeBio is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 5, 2022.

MLA

"AvengeBio — Funding & Investors." VCBacked, January 5, 2022, https://www.vcbacked.co/company/avengebio. Accessed July 3, 2026.

APA

VCBacked. (2022). AvengeBio — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/avengebio

Wikipedia (cite web)

{{cite web |title=AvengeBio — Funding & Investors |url=https://www.vcbacked.co/company/avengebio |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 5, 2022.